Page last updated: 2024-09-05

sb 216763 and Pituitary Neoplasms

sb 216763 has been researched along with Pituitary Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bai, G; Cao, L; Gao, H; Gui, S; Lu, R; Wang, F; Zhang, Y	1

Other Studies

1 other study(ies) available for sb 216763 and Pituitary Neoplasms

Article	Year
Effects of the estrogen receptor antagonist fulvestrant on F344 rat prolactinoma models. Journal of neuro-oncology, 2014, Volume: 116, Issue:3 Topics: Animals; Cell Line, Transformed; Disease Models, Animal; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Extracellular Matrix Proteins; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Indoles; Intercellular Signaling Peptides and Proteins; Maleimides; Pituitary Neoplasms; Prolactin; Prolactinoma; Rats; Rats, Inbred F344; Time Factors	2014

Article

Year

Effects of the estrogen receptor antagonist fulvestrant on F344 rat prolactinoma models.

Journal of neuro-oncology, 2014, Volume: 116, Issue:3

Topics: Animals; Cell Line, Transformed; Disease Models, Animal; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Extracellular Matrix Proteins; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Indoles; Intercellular Signaling Peptides and Proteins; Maleimides; Pituitary Neoplasms; Prolactin; Prolactinoma; Rats; Rats, Inbred F344; Time Factors

2014